Literature DB >> 12553877

Expression and role of mannose receptor/terminal high-mannose type oligosaccharide on osteoclast precursors during osteoclast formation.

S Morishima1, I Morita, T Tokushima, H Kawashima, M Miyasaka, K Omura, S Murota.   

Abstract

Osteoclasts are formed from hematopoietic precursors via cell-cell fusion. We have previously reported that mannose residues are expressed on the outer membranes of monocytes during osteoclast differentiation. In the present study, we have attempted to demonstrate the pattern of expression levels of terminal high-mannose type oligosaccharide and to show that the mannose receptor is expressed on osteoclast precursor cells. Osteoclasts were formed using three different systems, namely mouse bone marrow cell culture, co-culture of mouse spleen cells with stromal cells, and RAW264.7 cell cultures. During osteoclast differentiation, the expression of terminal high-mannose type oligosaccharide gradually increased and then peaked at the stage of fusion in all three systems. Expression of the mannose receptor gradually increased during osteoclast differentiation in bone marrow cells and the co-culture system. In contrast, that in RAW264.7 cells had already been detected in the absence of the soluble receptor activator of NF-kappaB ligand and did not change during osteoclast differentiation. To ascertain whether expression of high-mannose type oligosaccharide is involved in tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cell (MNC) formation, glycosidase inhibitors were used on RAW264.7 cell culture. Castanospermine, an inhibitor of glucosidase I, inhibited the TRAP-positive MNCs, and deoxymannojirimycin, an inhibitor of alpha-mannosidase I, increased the TRAP-positive MNC formation. These results indicate that the binding of terminal high-mannose and mannose receptor is important for the process of cellular fusion in osteoclast formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12553877     DOI: 10.1677/joe.0.1760285

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  8 in total

1.  Extensive determination of glycan heterogeneity reveals an unusual abundance of high mannose glycans in enriched plasma membranes of human embryonic stem cells.

Authors:  Hyun Joo An; Phung Gip; Jaehan Kim; Shuai Wu; Kun Wook Park; Cheryl T McVaugh; David V Schaffer; Carolyn R Bertozzi; Carlito B Lebrilla
Journal:  Mol Cell Proteomics       Date:  2011-12-06       Impact factor: 5.911

2.  High-mannose glycans are elevated during breast cancer progression.

Authors:  Maria Lorna A de Leoz; Lawrence J T Young; Hyun Joo An; Scott R Kronewitter; Jaehan Kim; Suzanne Miyamoto; Alexander D Borowsky; Helen K Chew; Carlito B Lebrilla
Journal:  Mol Cell Proteomics       Date:  2010-11-19       Impact factor: 5.911

Review 3.  Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis.

Authors:  Allen B Tu; Jamal S Lewis
Journal:  Drug Deliv Transl Res       Date:  2021-08-19       Impact factor: 4.617

4.  Regulation of neutrophil function by selective targeting of glycan epitopes expressed on the integrin CD11b/CD18.

Authors:  Matthias Kelm; Sylvain Lehoux; Veronica Azcutia; Richard D Cummings; Asma Nusrat; Charles A Parkos; Jennifer C Brazil
Journal:  FASEB J       Date:  2019-12-23       Impact factor: 5.191

5.  Mannose receptor regulates myoblast motility and muscle growth.

Authors:  Katie M Jansen; Grace K Pavlath
Journal:  J Cell Biol       Date:  2006-07-24       Impact factor: 10.539

6.  O-GlcNAcylation mediates metastasis of cholangiocarcinoma through FOXO3 and MAN1A1.

Authors:  Chatchai Phoomak; Atit Silsirivanit; Dayoung Park; Kanlayanee Sawanyawisuth; Kulthida Vaeteewoottacharn; Chaisiri Wongkham; Eric W-F Lam; Chawalit Pairojkul; Carlito B Lebrilla; Sopit Wongkham
Journal:  Oncogene       Date:  2018-06-18       Impact factor: 9.867

7.  Expression and possible role of PVR/CD155/Necl-5 in osteoclastogenesis.

Authors:  Saori Kakehi; Ken-ichi Nakahama; Ikuo Morita
Journal:  Mol Cell Biochem       Date:  2007-02-08       Impact factor: 3.842

Review 8.  Nanobody: the "magic bullet" for molecular imaging?

Authors:  Rubel Chakravarty; Shreya Goel; Weibo Cai
Journal:  Theranostics       Date:  2014-01-29       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.